The acquisition of TrierHealth means Velocity can develop applications that harness the power of AI and data science to improve clinical research
US-based fully integrated clinical site organisation Velocity Clinical Research announced its acquisition of TrierHealth, a digital clinical trials platform whose R&D team operates out of Hyderabad, to develop patient-focussed technology. TrierHealth’s founder, Raghu Punnamraju, will become Velocity’s, Chief Technology Officer.
Velocity Clinical Research operates 30 locations across the US and will expand to other regions this year, adopting a hybrid solution of both brick-and-mortar sites plus technology elements to facilitate greater patient recruitment into clinical research globally, speeding up drug development.
In the past 12 months, Velocity has randomised 25,000 patients into phase II and III studies in the US Velocity will now embark on an aggressive recruitment drive for clinical technology talent in Hyderabad, critical to the company’s growth as a global clinical trials player.
Dr G Paul Evans, Chief Executive and President of Velocity Clinical Research said, “We’re building a global community of patients who are engaged, advocate for participation in clinical research, and actively take part in multiple studies. We looked to Hyderabad for its well-known reputation as a hub for technology development within Life Sciences. It has a qualified workforce with the expertise we are looking for that will allow us to scale the team in line with our ambitious growth objectives.
The acquisition of TrierHealth means Velocity can develop applications that harness the power of AI and data science to improve clinical research. The acquisition comes 18 months after collaborating with TrierHealth to build a patient-focused platform to support decentralised visits. The R&D team, based in Hyderabad, will now expand and focus on patient recruitment and retention applications.
